This Is MS Multiple Sclerosis Community: Knowledge & Support

A long way off but nice to hear all the same..

http://www.cnbc.com/id/33075381


RegeneRx jumps on positive preclinical study data

By: The Associated Press | 29 Sep 2009 | 02:29 PM ET Text Size
NEW YORK - Shares of RegeneRx Biopharmaceuticals Inc. surged to a new year high Tuesday after the company reported positive data from a preclinical study of its prospective multiple sclerosis treatment RGN-352.

RegeneRx said the drug improved the recovery of nerve function when it was tested on animals.

In afternoon trading, shares of the Bethesda, Md.-based company jumped 32 cents, or 39 percent, to $1.14. Earlier they traded as high as $1.95, eclipsing a previous 52-week high of $1.82 set in January.

RGN-352 is an injectable form of a peptide that slows inflammation, promotes cell differentiation and blood vessel growth, and encourages collagen depositing. The company said it is working to develop drugs that speed up tissue and organ repair.

RegeneRx recently finished an early stage human trial of RGN-352 as a treatment for patients who had suffered a heart attack. It is conducting animal studies of the drug as a treatment for ailments including stroke, ischemic kidney disease, and Crohn's disease.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Mice again..... but as ElMarino said nice to hear.

BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis) significantly improves neurological functional recovery. In addition to this neurological benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath), the control of which are important therapeutic goals.

The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Experimental Auto Encephalomyelitis,” was published online ahead of print in Neuroscience, 2009 September 24. The publication highlights the statistically significant effects of Tβ4 treatment in EAE mice, including improvement of neurological functional recovery, reduction of inflammatory infiltrates in the brain, and increase of oligodendrocyte progenitor cells (a type of stem cell) and mature oligodendrocytes in the brain.